| Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? D Trachootham, J Alexandre, P Huang Nature reviews Drug discovery 8 (7), 579-591, 2009 | 5740 | 2009 |
| Controlling tumor growth by modulating endogenous production of reactive oxygen species A Laurent, C Nicco, C Chéreau, C Goulvestre, J Alexandre, A Alves, ... Cancer research 65 (3), 948-956, 2005 | 614 | 2005 |
| Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer E Raymond, J Alexandre, S Faivre, K Vera, E Materman, J Boni, C Leister, ... Journal of clinical oncology 22 (12), 2336-2347, 2004 | 591 | 2004 |
| Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species J Alexandre, Y Hu, W Lu, H Pelicano, P Huang Cancer research 67 (8), 3512-3517, 2007 | 466 | 2007 |
| Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel‐induced cancer cell death both in vitro and in vivo J Alexandre, F Batteux, C Nicco, C Chéreau, A Laurent, L Guillevin, ... International journal of cancer 119 (1), 41-48, 2006 | 400 | 2006 |
| Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study SM Domchek, S Postel-Vinay, SA Im, YH Park, JP Delord, A Italiano, ... The Lancet Oncology 21 (9), 1155-1164, 2020 | 398 | 2020 |
| Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients A Yovine, M Riofrio, JY Blay, E Brain, J Alexandre, C Kahatt, A Taamma, ... Journal of Clinical Oncology 22 (5), 890-899, 2004 | 386 | 2004 |
| Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir J Alexandre, C Nicco, C Chéreau, A Laurent, B Weill, F Goldwasser, ... Journal of the National Cancer Institute 98 (4), 236-244, 2006 | 243 | 2006 |
| Sorafenib-Induced Hepatocellular Carcinoma Cell Death Depends on Reactive Oxygen Species Production In Vitro and In Vivo R Coriat, C Nicco, C Chéreau, O Mir, J Alexandre, S Ropert, B Weill, ... Molecular cancer therapeutics 11 (10), 2284-2293, 2012 | 223 | 2012 |
| Pharmacokinetics and toxicity of docetaxel: Role of CYP3A, MDR1, and GST polymorphisms A Tran, V Jullien, J Alexandre, E Rey, F Rabillon, V Girre, V Dieras, ... Clinical pharmacology & therapeutics 79 (6), 570-580, 2006 | 180 | 2006 |
| Evaluation of the nutritional and inflammatory status in cancer patients for the risk assessment of severe haematological toxicity following chemotherapy J Alexandre, M Gross-Goupil, B Falissard, ML Nguyen, JM Gornet, ... Annals of Oncology 14 (1), 36-41, 2003 | 174 | 2003 |
| Randomized phase III trial of irinotecan plus cisplatin compared with paclitaxel plus carboplatin as first-line chemotherapy for ovarian clear cell carcinoma: JGOG3017/GCIG trial T Sugiyama, A Okamoto, T Enomoto, T Hamano, E Aotani, Y Terao, ... Journal of clinical oncology 34 (24), 2881-2887, 2016 | 148 | 2016 |
| Dimethyl fumarate, a two‐edged drug: current status and future directions NEB Saidu, N Kavian, K Leroy, C Jacob, C Nicco, F Batteux, J Alexandre Medicinal research reviews 39 (5), 1923-1952, 2019 | 143 | 2019 |
| Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial P Pautier, A Floquet, C Chevreau, N Penel, C Guillemet, C Delcambre, ... The Lancet Oncology 16 (4), 457-464, 2015 | 142 | 2015 |
| Relation between hypermetabolism, cachexia, and survival in cancer patients: a prospective study in 390 cancer patients before initiation of anticancer therapy1, 2 C Vazeille, A Jouinot, JP Durand, N Neveux, P Boudou-Rouquette, ... The American journal of clinical nutrition 105 (5), 1139-1147, 2017 | 130 | 2017 |
| Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) T Bachelot, E Ciruelos, A Schneeweiss, F Puglisi, T Peretz-Yablonski, ... Annals of Oncology 30 (5), 766-773, 2019 | 123 | 2019 |
| Gynecologic Cancer InterGroup (GCIG) consensus review for mucinous ovarian carcinoma JA Ledermann, D Luvero, A Shafer, D O’Connor, G Mangili, M Friedlander, ... International Journal of Gynecological Cancer 24, S14-S19, 2014 | 115 | 2014 |
| Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum–paclitaxel-based chemotherapy, the GINECO experience J Alexandre, I Ray-Coquard, F Selle, A Floquet, P Cottu, B Weber, ... Annals of oncology 21 (12), 2377-2381, 2010 | 109 | 2010 |
| Stage I non-seminomatous germ-cell tumours of the testis: identification of a subgroup of patients with a very low risk of relapse J Alexandre, K Fizazi, C Mahe, S Culine, JP Droz, C Théodore, ... European Journal of Cancer 37 (5), 576-582, 2001 | 105 | 2001 |
| Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer DM O'Malley, A Oaknin, BJ Monk, F Selle, C Rojas, L Gladieff, D Berton, ... Gynecologic oncology 163 (2), 274-280, 2021 | 104 | 2021 |
Joël CosteUniversité Paris Cité, Ecole Pratique des Hautes EtudesE-mail megerősítve itt: parisdescartes.fr